Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hemophilia A And Graves' Focus For Freshly Financed Apitope

This article was originally published in Scrip

Executive Summary

Few will remember Apitope. Those that do will remember it had a good run in 2008, with a series A financing and a licensing deal with Merck Serono for its lead program in multiple sclerosis (MS), and then…near radio silence. Until now. Suddenly that distant MS candidate ATX MS 1467 is Merck Serono's second-to-last remaining hope as a successor to Rebif. And Apitope has two more interesting compounds ready for clinical testing – for hemophilia A and Graves' disease – and the money to fund them with a €12m series B financing announced this week. Scrip's Sukaina Virji caught up with CEO Dr Keith Martin.


Related Content

Apitope Upbeat After Merck Returns Multiple Sclerosis Candidate


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts